New hope to halt river blindness: testing a Twice-Yearly treatment
NCT ID NCT03876262
Summary
This trial is testing if a drug called moxidectin, given once or twice a year, is safe and works better than the current standard drug, ivermectin, to control the parasite that causes river blindness. It involves 323 people in the Democratic Republic of Congo who already have the infection. The main goal is to see which treatment schedule best keeps the skin clear of the parasite for a full year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ONCHOCERCIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre de Recherche pour les Maladies Tropicales Negligees
Rethy, Ituri, Democratic Republic of the Congo
Conditions
Explore the condition pages connected to this study.